For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Sales of products and services | 0 | 12,353* | 0 | 0 |
| Cost of goods and services sold | 0 | 4,188* | 0 | 0 |
| Gross profit | 0 | 8,165 | 0 | 0 |
| Other operating expenses | - | - | 26,758 | -29,032 |
| Employee compensation | 191,790 | 184,355 | 192,869 | 183,864 |
| Occupancy | 28,190 | -155,233 | 46,920 | 49,723 |
| Depreciation and amortization of property and equipment | 25,745 | 104,077.5* | 41,893 | 41,744 |
| Amortization of intangible assets | 3,326 | 1,738 | 1,694 | 3,400 |
| Other operating expenses | 40,223 | 33,791.5* | - | - |
| Total operating expenses | 289,274 | 168,729 | 310,134 | 249,699 |
| Income (loss) from operations | -289,274 | -160,564 | -310,134 | -249,699 |
| Loss on obsolete inventory | - | - | 0 | 0 |
| Loss on obsolescence inventory | - | 0* | - | - |
| Interest expense | - | - | 18 | 23 |
| Interest income (expense) | - | -183* | - | - |
| Other income (expense) | -5,752 | -183 | -18 | -23 |
| Total other income (expenses) | -5,752 | - | - | - |
| Loss before provision for income tax | -295,026 | -160,747 | -310,152 | -249,722 |
| Provision for income tax | 0 | 0 | 0 | 0 |
| Net loss | -295,026 | -160,747 | - | -249,722 |
| Net loss attributable to non-controlling interest | -22,418 | -24,233 | -33,381 | -19,389 |
| Net loss attributable to common stockholders | - | -136,514 | -276,771 | - |
| Net loss attributable to common stockholders | -272,608 | - | -310,152 | -230,333 |
| Diluted EPS | 0 | -0.001 | 0 | 0 |
| Diluted Average Shares | 170,420,790 | 171,067,230 | 147,870,790 | 119,820,790 |
Yubo International Biotech Ltd (YBGJ)
Yubo International Biotech Ltd (YBGJ)